Matinas BioPharma Holdings Inc
$ 0.55
9.80%
20 Apr - close price
- Market Cap 3,203,100 USD
- Current Price $ 0.55
- High / Low $ 0.56 / 0.49
- Stock P/E N/A
- Book Value 0.75
- EPS -2.00
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -1.67 %
- 52 Week High 3.09
- 52 Week Low 0.48
About
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of several candidate products. The company is headquartered in Bedminster, New Jersey.
Analyst Target Price
$30.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-26 | 2025-11-10 | 2025-08-13 | 2025-04-15 | 2025-03-25 | 2024-11-13 | 2024-08-07 | 2024-05-09 | 2024-01-09 | 2023-11-08 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.2985 | -0.4 | -1.03 | -0.81 | -0.8056 | -0.85 | -0.02 | -0.03 | -0.02 | -0.03 | -0.03 | -0.03 |
| Estimated EPS | None | None | None | -0.78 | -0.78 | -1.05 | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Surprise | 0 | 0 | 0 | -0.03 | -0.0256 | 0.2 | 0 | 0 | 0.01 | 0 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | -3.8462% | -3.2821% | 19.0476% | 0% | 0% | 33.3333% | 0% | 0% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MTNB
2026-04-18 14:40:19
This article focuses on the net current asset value per share of Matinas BioPharma Holdings, Inc. (FWB:6LJ0). It provides a financial overview of the company's stock on the Frankfurt Stock Exchange. The content is primarily a data placeholder from TradingView, indicating where specific financial data for Matinas BioPharma Holdings, Inc. would be displayed.
2026-04-04 03:09:45
Matinas BioPharma received a non-compliance notice from NYSE American on April 2, 2026, due to insufficient shareholder equity of $4.83 million as of December 31, 2025. The company must submit a compliance plan by May 2, 2026, and has 18 months to regain compliance. Continuous losses over the past five fiscal years have removed any exemption eligibility, increasing financial and operational pressures.
2026-04-03 21:09:18
Matinas BioPharma (NYSE: MTNB) has received a notice from NYSE American for non-compliance with continued listing standards, specifically concerning stockholders' equity. The company had $4.83 million in equity as of December 31, 2025, falling below the required thresholds due to losses over the past five fiscal years. Matinas has until May 2, 2026, to submit a remediation plan and may be granted an 18-month cure period to regain compliance, with its shares continuing to trade on the NYSE American during this review.
2026-04-03 21:09:18
Matinas BioPharma (MTNB) received a notice from NYSE American for non-compliance with equity requirements due to low stockholders' equity and losses over the past five years. The company must submit a compliance plan by May 2, 2026, and could face delisting proceedings if the plan is not accepted, although trading continues without immediate impact. This notice follows an original SEC filing from April 3, 2026.
2026-04-03 21:09:18
Matinas BioPharma (MTNB) has received a notice from NYSE American for non-compliance with listing standards due to low stockholders' equity ($4.83 million against a $6.0 million requirement) and five consecutive years of losses. The company has until May 2, 2026, to submit a compliance plan, with a potential 18-month cure period. The auditor's report also raises substantial doubt about Matinas BioPharma's ability to continue as a going concern, highlighting significant financial strain and delisting risk.
2026-03-20 21:09:12
This article analyzes the valuation of Matinas BioPharma Holdings Inc (MTNB), indicating it is currently in the "Fair zone" based on its forward PS ratio relative to its five-year average. It examines various financial metrics such as Price-to-Book ratio, Forward Free Cash Flow yield, and compares its P/S ratio to competitors. The analysis also addresses whether MTNB is overvalued or undervalued and provides its fair value range.
